The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Treatment patterns in patients with AL amyloidosis after failure of frontline Dara-VCd
In this video, Saurabh Zanwar, MD, Mayo Clinic, Rochester, MN, discusses treatment patterns in patients with light chain (AL) amyloidosis after failure of daratumumab, bortezomib, cyclophosphamide and dexamethasone (Dara-VCd). He highlights that patients with a suboptimal response to this regimen have limited treatment options, with an option to switch the VCd component. Dr Zanwar then discusses the findings of a study which found that patients with a suboptimal response to Dara-VCd either switched to a daratumumab- or venetoclax-based regimen, or underwent autologous stem cell transplant (autoSCT). This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
